多组分药物(MCD)可以诱导覆盖多个水平的各种细胞变化,从分子和亚细胞结构到细胞形态。MCD研究非常需要一种“非侵入性”方法来全面检测亚细胞水平上细胞精细结构和化学成分的动态变化。在这项研究中,多组分药物治疗后胃癌BGC823细胞的亚细胞动力学过程,复方苦参注射液(CKI),是用自制的,高分辨率,共聚焦拉曼光谱(RS)装置结合明场成像。原子核的拉曼光谱,对于以不同时间和剂量用CKI处理的每个细胞,同时收集细胞质和细胞内囊泡(0.4-1μm)。RS测量显示CKI降低了DNA特征,这种药物是已知的抑制。同时,观察并讨论了CKI诱导的亚细胞内大量囊泡外观的动态变化和胞质成分的解构。结果表明,高分辨率亚细胞显微拉曼光谱具有检测药物诱导的精细细胞动态变化和筛选癌症治疗中的MCD的潜力。
Multi-component drugs (MCDs) can induce various cellular changes covering multiple levels, from molecular and
subcellular structure to cell morphology. A \"non-invasive\" method for comprehensively detecting the dynamic changes of cellular fine structure and chemical components on the
subcellular level is highly desirable for MCD studies. In this study, the
subcellular dynamic processes of gastric cancer BGC823 cells after treatment with a multi-component drug, Compound Kushen Injection (CKI), were investigated using a homemade, high-resolution, confocal Raman spectroscopy (RS) device combined with bright-field imaging. The Raman spectra of the nucleus, cytoplasm and intracellular vesicles (0.4-1 μm) were collected simultaneously for each cell treated with CKI at different times and doses. The RS measurements showed that CKI decreased the DNA signatures, which the drug is known to inhibit. Meanwhile, the CKI-induced
subcellular dynamic changes in the appearance of numerous intracellular vesicles and the deconstruction of cytoplasm components were observed and discussed. The results demonstrated that high-resolution
subcellular micro-Raman spectroscopy has potential for detecting fine cellular dynamic variation induced by drugs and the screening of MCDs in cancer therapy.